Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2019

17.12.2018 | Review

Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients

verfasst von: Akshay Shetty, Adam Buch, Sammy Saab

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

As the demand for liver transplantation continues to rise, the scarcity of liver donor grafts has led to the use of extended criteria grafts for liver transplantation in select group of patients. Hepatitis C-seropositive liver grafts have been used primarily in hepatitis C-positive recipients, with studies showing non-inferior outcomes when compared to hepatitis C-negative grafts. Studies suggest that hepatitis C serology status of the donor liver does not influence the patient or graft outcomes in the recipient. These results advocate for offering hepatitis C-positive grafts to all patients awaiting liver transplantation regardless of their hepatitis C status. However, some concerns persist regarding the ethics of potentially introducing a new infection into a patient that could progress to chronic liver disease following liver transplantation. The recent approval of direct-acting antiviral therapy offers a solution to this dilemma, as it has changed the landscape of hepatitis C management by making it a curable disease. In this review, we shall discuss the current evidence regarding the use of hepatitis C-seropositive donor grafts in hepatitis C-positive and hepatitis C-negative patients.
Literatur
1.
Zurück zum Zitat Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 annual data report: liver. Am J Transplant. 2018;18:172–253.CrossRef Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 annual data report: liver. Am J Transplant. 2018;18:172–253.CrossRef
2.
Zurück zum Zitat Estes C, Anstee QM, Teresa Arias-Loste M et al. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.CrossRefPubMed Estes C, Anstee QM, Teresa Arias-Loste M et al. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.CrossRefPubMed
4.
Zurück zum Zitat Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153:113–122.CrossRefPubMed Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153:113–122.CrossRefPubMed
5.
Zurück zum Zitat Sanchez-Tapias JM, Rodes J. Dilemmas of organ transplantation from anti-HCV-positive donors. Lancet. 1995;345:469–470.CrossRefPubMed Sanchez-Tapias JM, Rodes J. Dilemmas of organ transplantation from anti-HCV-positive donors. Lancet. 1995;345:469–470.CrossRefPubMed
6.
Zurück zum Zitat Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2013 annual data report: liver. Am J Transplant. 2015;15:1–28.CrossRefPubMed Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2013 annual data report: liver. Am J Transplant. 2015;15:1–28.CrossRefPubMed
8.
Zurück zum Zitat Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65:804–812.CrossRefPubMed Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65:804–812.CrossRefPubMed
9.
Zurück zum Zitat Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.CrossRefPubMed Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.CrossRefPubMed
10.
Zurück zum Zitat El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767–1775.CrossRefPubMedPubMedCentral El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767–1775.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Bowring MG, Kucirka LM, Massie AB, et al. Changes in utilization and discard of hepatitis C-infected donor livers in the recent era. Am J Transplant. 2017;17:519–527.CrossRefPubMed Bowring MG, Kucirka LM, Massie AB, et al. Changes in utilization and discard of hepatitis C-infected donor livers in the recent era. Am J Transplant. 2017;17:519–527.CrossRefPubMed
14.
Zurück zum Zitat Shaffer AA, Thomas AG, Bowring MG, et al. Changes in practice and perception of hepatitis C and liver transplantation: results of a national survey. Transpl Infect Dis. 2018;20:e12982.CrossRefPubMed Shaffer AA, Thomas AG, Bowring MG, et al. Changes in practice and perception of hepatitis C and liver transplantation: results of a national survey. Transpl Infect Dis. 2018;20:e12982.CrossRefPubMed
15.
Zurück zum Zitat Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012;55:43–48.CrossRef Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012;55:43–48.CrossRef
16.
Zurück zum Zitat Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297:724–732.CrossRefPubMed Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297:724–732.CrossRefPubMed
17.
Zurück zum Zitat Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: is the ‘best’ test the right test? A consensus conference report. Am J Transplant. 2010;10:889–899.CrossRefPubMed Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: is the ‘best’ test the right test? A consensus conference report. Am J Transplant. 2010;10:889–899.CrossRefPubMed
18.
Zurück zum Zitat Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med. 2011;364:236–247.CrossRefPubMed Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med. 2011;364:236–247.CrossRefPubMed
19.
Zurück zum Zitat Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17:2790–2802.CrossRefPubMed Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17:2790–2802.CrossRefPubMed
20.
Zurück zum Zitat Testa G, Goldstein RM, Netto G, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation. 1998;65:925–929.CrossRefPubMed Testa G, Goldstein RM, Netto G, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation. 1998;65:925–929.CrossRefPubMed
21.
Zurück zum Zitat Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999;117:149–153.CrossRefPubMed Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999;117:149–153.CrossRefPubMed
22.
Zurück zum Zitat Torres M, Weppler D, Reddy KR, Tzakis A. Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients. Gastroenterology. 1999;117:1253.CrossRefPubMed Torres M, Weppler D, Reddy KR, Tzakis A. Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients. Gastroenterology. 1999;117:1253.CrossRefPubMed
23.
Zurück zum Zitat Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384–394.CrossRefPubMedPubMedCentral Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384–394.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Álvaro E, Abradelo M, Fuertes A, et al. Liver transplantation from anti-hepatitis C virus-positive donors: our experience. Transplant Proc. 2012;44:1475–1478.CrossRefPubMed Álvaro E, Abradelo M, Fuertes A, et al. Liver transplantation from anti-hepatitis C virus-positive donors: our experience. Transplant Proc. 2012;44:1475–1478.CrossRefPubMed
25.
Zurück zum Zitat Ricchiuti A, Brunati A, Mirabella S, Pierini A, Franchello A, Salizzoni M. Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience. Transplant Proc. 2005;37:2569–2570.CrossRefPubMed Ricchiuti A, Brunati A, Mirabella S, Pierini A, Franchello A, Salizzoni M. Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience. Transplant Proc. 2005;37:2569–2570.CrossRefPubMed
26.
Zurück zum Zitat Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation. 2002;73:582–587.CrossRefPubMed Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation. 2002;73:582–587.CrossRefPubMed
27.
Zurück zum Zitat Saab S, Ghobrial RM, Ibrahim AB, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant. 2003;3:1167–1172.CrossRefPubMed Saab S, Ghobrial RM, Ibrahim AB, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant. 2003;3:1167–1172.CrossRefPubMed
28.
Zurück zum Zitat Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV + allografts. Liver Transplant. 2006;12:1496–1503.CrossRef Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV + allografts. Liver Transplant. 2006;12:1496–1503.CrossRef
29.
Zurück zum Zitat Lai JC, O’Leary JG, Trotter JF, et al. Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transplant. 2012;18:532–538.CrossRef Lai JC, O’Leary JG, Trotter JF, et al. Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transplant. 2012;18:532–538.CrossRef
30.
Zurück zum Zitat Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transplant. 2001;7:762–768.CrossRef Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transplant. 2001;7:762–768.CrossRef
31.
Zurück zum Zitat Peek R, Reddy KR. Hepatitis C virus-infected donors in liver transplantation. Gastroenterology. 2007;133:381–382.CrossRefPubMed Peek R, Reddy KR. Hepatitis C virus-infected donors in liver transplantation. Gastroenterology. 2007;133:381–382.CrossRefPubMed
32.
Zurück zum Zitat Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23:1038–1044.CrossRefPubMed Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23:1038–1044.CrossRefPubMed
33.
Zurück zum Zitat Ballarin R, Cucchetti A, Spaggiari M, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91:1265–1272.CrossRefPubMed Ballarin R, Cucchetti A, Spaggiari M, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91:1265–1272.CrossRefPubMed
34.
Zurück zum Zitat Stepanova M, Sayiner M, de Avila L, Younoszai Z, Racila A, Younossi ZM. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. BMC Gastroenterol. 2016;16:137.CrossRefPubMedPubMedCentral Stepanova M, Sayiner M, de Avila L, Younoszai Z, Racila A, Younossi ZM. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. BMC Gastroenterol. 2016;16:137.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat O’Leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transplant Int. 2012;25:825–829.CrossRef O’Leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transplant Int. 2012;25:825–829.CrossRef
36.
Zurück zum Zitat Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology. 1999;29:1220–1226.CrossRefPubMed Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology. 1999;29:1220–1226.CrossRefPubMed
37.
Zurück zum Zitat Bari K, Luckett K, Kaiser T, et al. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients. Hepatology. 2018;67:1673–1682.CrossRefPubMed Bari K, Luckett K, Kaiser T, et al. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients. Hepatology. 2018;67:1673–1682.CrossRefPubMed
38.
Zurück zum Zitat Watanabe T, Koyama I, Shinozuka N, et al. A case of renal transplantation received from a living donor with second-generation anti-hepatitis C virus antibody positive into an anti-hepatitis C virus antibody negative recipient. Transplant Proc. 2000;32:1593–1594.CrossRefPubMed Watanabe T, Koyama I, Shinozuka N, et al. A case of renal transplantation received from a living donor with second-generation anti-hepatitis C virus antibody positive into an anti-hepatitis C virus antibody negative recipient. Transplant Proc. 2000;32:1593–1594.CrossRefPubMed
39.
Zurück zum Zitat Cruzado JM, Gil-Vernet S, Castellote J, Bestard O, Melilli E, Grinyo JM. Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient. Am J Transplant. 2013;13:2773–2774.CrossRefPubMed Cruzado JM, Gil-Vernet S, Castellote J, Bestard O, Melilli E, Grinyo JM. Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient. Am J Transplant. 2013;13:2773–2774.CrossRefPubMed
40.
Zurück zum Zitat Bouatou Y, Negro F, Hadaya K. ABO incompatible kidney transplantation from an anti-hepatitis C virus antibody-positive RNA-negative donor into an anti-hepatitis C virus antibody-negative recipient. Transplant Int. 2015;28:127–128.CrossRef Bouatou Y, Negro F, Hadaya K. ABO incompatible kidney transplantation from an anti-hepatitis C virus antibody-positive RNA-negative donor into an anti-hepatitis C virus antibody-negative recipient. Transplant Int. 2015;28:127–128.CrossRef
41.
Zurück zum Zitat Unagami K, Ishida H, Okumi M, et al. Assessment of 4 cases of kidney transplantation from hepatitis C virus antibody-positive and RNA-negative donors to antibody-negative recipients. Transplant Direct. 2016;2:102.CrossRef Unagami K, Ishida H, Okumi M, et al. Assessment of 4 cases of kidney transplantation from hepatitis C virus antibody-positive and RNA-negative donors to antibody-negative recipients. Transplant Direct. 2016;2:102.CrossRef
42.
Zurück zum Zitat Agarwal N, Davis R, Gracey D, et al. Detection of hepatitis C antibodies without viral transmission in hepatitis C-negative recipients receiving kidneys from hepatitis C-positive donors treated with direct-acting antiviral therapy. Transplantation. 2018;102:121–122. Agarwal N, Davis R, Gracey D, et al. Detection of hepatitis C antibodies without viral transmission in hepatitis C-negative recipients receiving kidneys from hepatitis C-positive donors treated with direct-acting antiviral therapy. Transplantation. 2018;102:121–122.
45.
Zurück zum Zitat Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168:533–540.CrossRefPubMedPubMedCentral Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168:533–540.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376:2394–2395.CrossRefPubMed Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376:2394–2395.CrossRefPubMed
47.
Zurück zum Zitat Reese PP, Abt PL, Blumberg EA, Van Deerlin VM, Bloom RD, Potluri VS, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med. 2018;169:273–281.CrossRefPubMed Reese PP, Abt PL, Blumberg EA, Van Deerlin VM, Bloom RD, Potluri VS, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med. 2018;169:273–281.CrossRefPubMed
48.
Zurück zum Zitat Gudmundsson GS, Malinowska K, Robinson JA, et al. Five-year follow-up of hepatitis C-naive heart transplant recipients who received hepatitis C-positive donor hearts. Transplant Proc. 2003;35:1536–1538.CrossRefPubMed Gudmundsson GS, Malinowska K, Robinson JA, et al. Five-year follow-up of hepatitis C-naive heart transplant recipients who received hepatitis C-positive donor hearts. Transplant Proc. 2003;35:1536–1538.CrossRefPubMed
49.
Zurück zum Zitat Englum BR, Ganapathi AM, Speicher PJ, et al. Impact of donor and recipient hepatitis C status in lung transplantation. J Heart Lung Transplant. 2016;35:228–235.CrossRefPubMed Englum BR, Ganapathi AM, Speicher PJ, et al. Impact of donor and recipient hepatitis C status in lung transplantation. J Heart Lung Transplant. 2016;35:228–235.CrossRefPubMed
50.
Zurück zum Zitat Saberi B, Hamilton JP, Durand CM, et al. Utilization of hepatitis C RNA-positive donor liver for transplant to hepatitis C RNA-negative recipient. Liver Transplant. 2017;24:140–143.CrossRef Saberi B, Hamilton JP, Durand CM, et al. Utilization of hepatitis C RNA-positive donor liver for transplant to hepatitis C RNA-negative recipient. Liver Transplant. 2017;24:140–143.CrossRef
51.
Zurück zum Zitat Campos-Varela I, Agudelo E, Sarkar M, Roberts J, Terrault N. Use of hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA negative liver transplant recipient. Transplant Infect Dis. 2018;20:e12809.CrossRef Campos-Varela I, Agudelo E, Sarkar M, Roberts J, Terrault N. Use of hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA negative liver transplant recipient. Transplant Infect Dis. 2018;20:e12809.CrossRef
52.
Zurück zum Zitat Renz JF, Kin C, Kinkhabwala M, et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg. 2005;242:556–563. (discussion 563–555).PubMedPubMedCentral Renz JF, Kin C, Kinkhabwala M, et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg. 2005;242:556–563. (discussion 563–555).PubMedPubMedCentral
53.
Zurück zum Zitat Selck FW, Grossman EB, Ratner LE, Renz JF. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool. Ann Surg. 2008;248:599–607.PubMed Selck FW, Grossman EB, Ratner LE, Renz JF. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool. Ann Surg. 2008;248:599–607.PubMed
54.
Zurück zum Zitat Tector AJ, Mangus RS, Chestovich P, et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg. 2006;244:439–450.PubMedPubMedCentral Tector AJ, Mangus RS, Chestovich P, et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg. 2006;244:439–450.PubMedPubMedCentral
55.
Zurück zum Zitat Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10:1238–1246.CrossRefPubMed Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10:1238–1246.CrossRefPubMed
56.
Zurück zum Zitat Cywinski JB, Mascha EJ, You J, et al. Pre-transplant MELD and sodium MELD scores are poor predictors of graft failure and mortality after liver transplantation. Hepatol Int. 2011;5:841–849.CrossRefPubMed Cywinski JB, Mascha EJ, You J, et al. Pre-transplant MELD and sodium MELD scores are poor predictors of graft failure and mortality after liver transplantation. Hepatol Int. 2011;5:841–849.CrossRefPubMed
57.
Zurück zum Zitat Rana A, Hardy MA, Halazun KJ, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant. 2008;8:2537–2546.CrossRefPubMed Rana A, Hardy MA, Halazun KJ, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant. 2008;8:2537–2546.CrossRefPubMed
58.
Zurück zum Zitat Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108–117.CrossRefPubMed Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108–117.CrossRefPubMed
59.
Zurück zum Zitat Ueda Y, Ikegami T, Akamatsu N, et al. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. J Gastroenterol. 2017;52:986–991.CrossRefPubMed Ueda Y, Ikegami T, Akamatsu N, et al. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. J Gastroenterol. 2017;52:986–991.CrossRefPubMed
60.
Zurück zum Zitat Reau N, Kwo PY, Rhee S. MAGELLAN-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1–6 Infection. Paper presented at: EASL International Liver Meeting, April; 2017. Reau N, Kwo PY, Rhee S. MAGELLAN-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1–6 Infection. Paper presented at: EASL International Liver Meeting, April; 2017.
61.
Zurück zum Zitat Saab S, Kardashian A, Saggi S, Choi G, Agopian V, Tong MJ. Use of hepatitis C positive grafts in hepatitis C negative liver transplant recipients is cost-effective. Clin Transplant. 2018;32:e13383.CrossRefPubMed Saab S, Kardashian A, Saggi S, Choi G, Agopian V, Tong MJ. Use of hepatitis C positive grafts in hepatitis C negative liver transplant recipients is cost-effective. Clin Transplant. 2018;32:e13383.CrossRefPubMed
Metadaten
Titel
Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients
verfasst von
Akshay Shetty
Adam Buch
Sammy Saab
Publikationsdatum
17.12.2018
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2019
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5404-x

Weitere Artikel der Ausgabe 5/2019

Digestive Diseases and Sciences 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.